BIVI Stock, BioVie Inc. Information

BioVie Inc. is a clinical stage company pursuing the discovery, development, and commercialization of innovative drug therapies in liver disease. The Company is focused on commercializing BIV , a novel approach to the treatment of ascites due to chronic liver cirrhosis. Liver cirrhosis claims approximately , American lives each year. The FDA has never approved any drugs specifically for treating ascites and there is a substantial unmet medical need. The Company s new drug candidate BIV has Orphan Drug designation and is patented in the US. In early , the Company s investigational new drug IND application was cleared by the FDA to begin a Phase a clinical trial. This patient trial is being conducted at the McGuire Research Institute in Richmond, VA. As of year end , refractory ascites patients had been treated with BIV .